Acadia Pharma loses $85.3 million in first quarter May 2, 2019 sandiegobiotech News Comments Off on Acadia Pharma loses $85.3 million in first quarter Acadia Pharma loses $85.3 million in first quarter Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds 00:00 / Subscribe Share RSS Feed Share Link Embed However, sales of flagship drug Nuplazid — the only FDA-approved treatment for Parkinson’s disease psychosis — increase